Claims for Patent: 9,433,679

Summary for Patent: 9,433,679

Title:	Use of TRMP8 for treating opthalmic diseases or conditions involving tearing
Abstract:	The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.
Inventor(s):	Carlos Belmonte Martínez, Juana Gallar Martínez, Antonio Ferrer Montiel, Asia Fernández Carvajal, Félix Viana De La Iglesia
Assignee:	Consejo Superior de Investigaciones Cientificas CSIC , Universidad Miguel Hernandez de Elche UMH
Application Number:	US14/699,873
Patent Claims:	1. A method for treating an ophthalmic disease or condition, said disease or condition involving tearing and/or relieving symptoms thereof comprising administering a therapeutically effective amount of a composition comprising a molecule binding specifically to the TRPM8(Transient receptor potential cation channel subfamily M member 8) receptor to a subject in need thereof, (i) wherein the binding of the molecule to the TRPM8 receptor modulates the activity of the TRPM8 channel; (ii) wherein the binding of the molecule to the TRPM8 receptor increases or decreases tear secretion caused by the ophthalmic disease or condition; and (iii) wherein the amount of the molecule binding specifically to the TRPM8 receptor is not cytotoxic to the subject in need thereof. 2. The method according to claim 1, wherein the molecule binding specifically to the TRPM8 receptor is a TRPM8 receptor agonist. 3. The method according to claim 1, wherein the molecule binding specifically to the TRPM8 receptor is a TRPM8 receptor antagonist. 4. The method according to claim 2, wherein the ophthalmic disease or condition is xerophthalmia. 5. The method according to claim 3, wherein the ophthalmic disease or condition is epiphora. 6. The method according to claim 4, wherein the xerophthalmia is associated with a disease or condition selected from the group consisting of vitamin A deficit, Sjogren syndrome, rheumatologic diseases, and burns. 7. The method according to claim 6, wherein the burns are chemical burns or thermal burns. 8. The method according to claim 6, wherein the rheumatologic disease is rheumatoid arthritis. 9. The method according claim 5, wherein the epiphora is associated with a disease or condition selected from the group consisting of Graves-Basedow disease, corneal ulcers, Ackerman syndrome, allergies, bacterial conjunctivitis, blepharitis, facial nerve palsy, ectropion, obstruction of the nasolacrimal duct, and obstruction of the lacrimal sac. 10. The method according to claim 2, wherein the TRPM8 receptor agonist comprises a 5-methyl-2-isopropyl cyclohexane core structure. 11. The method according to claim 10, wherein the TRPM8 receptor agonist is selected from the group consisting of WS-5, CPS-369, CPS-368, CPS-125, menthyl lactate, menthone glycerin acetal Coolant Agent 10, (−)-Isopulegol, Cubelol, Hasegawa's cooling compound, WS-11, WS-12, WS-30, WS-3, WS-14, menthol, IFF' s New GRASS cooling material, and combinations thereof. 12. The method according to claim 10, wherein the TRPM8 receptor agonist is WS12. 13. The method to claim 3, wherein the TRPM8 receptor antagonist comprises a 5-methyl-2-isopropyl cyclohexane core structure. 14. The method according to claim 13, wherein the TRPM8 receptor antagonist is selected from the group consisting of MAD1d, MAD2e, and combinations thereof. 15. The method according to claim 1, wherein the molecule binding specifically to the TRPM8 receptor can be administered a variable number of times a day. 16. The method according to claim 1, wherein the molecule binding specifically to the TRPM8 receptor can be administered from 1 to 4 times a day. 17. The method according to claim 2, wherein the composition comprises at least two TRPM8 agonists. 18. The method according to claim 3, wherein the composition comprises at least two TRPM8 antagonists. 19. The method according to claim 4, wherein the composition comprises a molecule binding specifically to the TRPM8 receptor and comprises at least one additional drug useful for the treatment of xerophthalmia. 20. The method according to claim 19, wherein at least one additional drug useful for the treatment of xerophthalmia is selected from the group consisting of a corticoid, a vitamin, a muscarinic acetylcholine receptor agonist, an immunosuppressant, and a combination thereof. 21. The method according to claim 20, wherein the vitamin is vitamin A. 22. The method according to claim 21, wherein the muscarinic acetylcholine receptor agonist is pylocarpine. 23. The method according to claim 21, wherein the immunosuppressant is cyclosporine. 24. The method according to claim 5, wherein the composition comprises a molecule binding specifically to the TRPM8 receptor and comprises at least one additional drug useful for the treatment of epiphora. 25. The method according to claim 24, wherein at least one additional drug useful for the treatment of epiphora is an antibiotic. 26. The method according to claim 1, wherein the composition further comprises a lubricant. 27. The method according to claim 26, wherein the lubricant is selected from the group consisting of glycerol, hydroxypropyl methylcellulose, hydroxymethyl cellulose, carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, hyaluronic acid, castor oil, mineral oil, hypromellose, carbomer, and combinations thereof. 28. The method according to claim 1, wherein the subject is an animal subject. 29. The method according to claim 1, wherein the molecule binding specifically to the TRPM8 receptor is not menthol. 30. The method according to claim 4, wherein the symptoms of xerophthalmia are dryness sensation, ocular discomfort, or a combination thereof.